secwatch.observer — SEC 8-K summary
======================================

Issuer:     QSAM Biosciences, Inc. (—)
CIK:        0001310527
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001493152-24-005356
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

QSAM Biosciences to be acquired by Telix for ~$33.1M shares plus up to $90M CVRs
--------------------------------------------------------------------------------

- Telix will acquire QSAM via two-step merger; total base consideration ~$33.1M in Telix shares (at $7.5745/share).
- QSAM stockholders receive 0.876 Telix shares per pre-reverse-split share (est. $6.63/share value).
- Up to $90M in contingent value rights (CVRs) on regulatory/commercial milestones over 10 years.
- Reverse stock split (1:1000 to 1:2000) to be effected before close; all preferred converted.
- Lock-up agreements for officers/directors on Telix shares received for 12 months post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-005356

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer